Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07590934 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
NCT07590934: Recruiting Phase 1 study, sponsored by AstraZeneca.
NCT07590934 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 152 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (153% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07590934, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Primary Outcome
To assess the safety and tolerability of palacaparib (AZD9574) in combination with AZD2265 (FPI-2265).
Interventions
- DRUG AZD9574
- DRUG Docetaxel
- DRUG AZD2265 (FPI-2265)
- DRUG AZD2287 (Imaging agent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2029-09-25 |
| Phase | Phase 1 |
What NCT07590934 shows while recruiting
NCT07590934 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (153% higher).
The record links to 0 conditions, and to 4 interventions - of which AZD9574 is the first listed.
NCT07590934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07590934 about?
NCT07590934 is a clinical study titled "Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
What is the current status of trial NCT07590934?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2026-06-03. Estimated completion is 2029-09-25.
What interventions are being tested in trial NCT07590934?
The interventions under investigation include: AZD9574 (DRUG), Docetaxel (DRUG), AZD2265 (FPI-2265) (DRUG), AZD2287 (Imaging agent) (DRUG).
Who is sponsoring clinical trial NCT07590934?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07590934's enrollment target sits among peer trials
152 359th of 2000 higher than 1,638 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI